PATENT CLAIM ANALYSIS

Application Number: 15872025
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["435", "006110"]

Abstract:
The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.

Claim (Index 1):
A method of reducing cholesterol level or maintaining previously reduced cholesterol level in a human in need thereof, wherein the method comprises administering an antibody or antibody fragment to the human, wherein\n (i) the antibody or fragment specifically binds a proprotein convertase subtilisin/kexin type 9 (PCSK9) encoded by the nucleotide sequence of SEQ ID NO: 30, SEQ ID NO: 31 or SEQ ID NO: 37 and the antibody or fragment comprises heavy chain and light chain variable domains of alirocumab; and (ii) said human comprises said nucleotide sequence encoding PCSK9.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 86.0
- Lexical Diversity: 1.05263
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14331730', '15138912', '14457566', '14457536', '14472828']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.763634607166981
- 35 USC 102 Novelty (BERT): 0.6579750993731504
- Combined Prediction Score: 0.7530686563875979
- Mean Citation Score: 704.175696
- Max Citation Score: 709.31085
- Similarity Product: 618.7118350069643

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test